Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostamatinib in rheumatoid arthritis extension study
NCT00805467Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Aug 2008
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label trial of fostamatinib in rheumatoid arthritis (RA), sponsored by AstraZeneca. Started Aug 2008; status: terminated.
02
Drugs
fostamatinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00805467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00805467.